Biotech Values

[xray72]

One has to keep in mind as well that the 7x multiple of this years expected earnings is already based on the assumption of Teva entering the Lovenox market this year.
If this is not the case the current multiple is closer to 3x.
Given the uncertainties surrounding Momenta (and the many positive events that could happen anytime; t-lov failing, M-Copax, M118, etc.) I don't give much to 2012 earnings estimates.